## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	s)														
1. Name and Address of Reporting Person * Shah Sujal				Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BOULEVARD, SUITE 110				3. Date of Earliest Transaction (Month/Day/Year) 01/29/2019							X Officer (give title below) Other (specify below)  Chief Executive Officer					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person				
NEWARK (City		(State)	(Zip)													
		(3)		la. 15								-		ficially Own		7.37
1.Title of Security (Instr. 3)				2A. Deemed Execution Da ) any (Month/Day/		ate, if Code (Instr. 8		(			of (D) Ow Trai		ecurities Beneficially ing Reported		Ownership Form:	7. Nature of Indirect Beneficial Ownership
							Code	. V	Amount (	(A) or (D)	Price	u. 3 and 4)			or Indirect (I) (I) (Instr. 4)	
Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number of		Expiration Date of 1 (Month/Day/Year)		rities)	d Amount ying		9. Number of Derivative Securities Beneficially Owned	Ownersh Form of	11. Nature p of Indirect Beneficial Ownership (Instr. 4)	
	Security												Following Reported Transaction(s	Direct (E or Indirect (I)		
				Code	v	(A)	(D)	Date Exercisal	Expira ble Date	tion	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (right to buy)	\$ 8.43	01/29/2019		A		328,492		(1)	01/28	/2029	Common Stock	<sup>n</sup> 328,492	\$ 0	328,492	. D	
Repor	ting O	wners														

Donastina Coman Nama / Addison	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Shah Sujal C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BOULEVARD, SUITE 110 NEWARK, CA 94560	X		Chief Executive Officer			

## **Signatures**

/s/ Sujal Shah	01/31/2019
Signature of Reporting	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.